NASDAQ: IXHLIncannex Healthcare Inc Stock
$0.60-0.02 (-3.23%)
Updated Apr 17, 2025
IXHL Price
$0.60
Fair Value Price
$0.22
Market Cap
$10.72M
52 Week Low
$0.47
52 Week High
$3.55
P/E
-0.43x
P/B
11.1x
P/S
381.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$98.00k
Earnings
-$23.81M
Gross Margin
100%
Operating Margin
-24,086.73%
Profit Margin
-24,291.8%
Debt to Equity
10.51
Operating Cash Flow
-$16M
Beta
0.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IXHL Overview
Incannex Healthcare Ltd develops and sells medicinal cannabinoid products in Australia. It offers pharmaceutical-grade cannabinoid products under the Incannex brand name. Incannex Healthcare has a partnership with The Alfred Hospital and Novotech, and the Monash Trauma Group at the Department of Neuroscience, Monash University. Known as Impression Healthcare Ltd. until 2020, Incannex Healthcare was incorporated in 2001 and is based in Sydney, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IXHL's potential to beat the market
- IXHL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
IXHL
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important IXHL news, forecast changes, insider trades & much more!
IXHL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IXHL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IXHL ($0.60) is overvalued by 178.95% relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IXHL ($0.60) is not significantly undervalued (178.95%) relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IXHL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IXHL due diligence checks available for Premium users.
Valuation
IXHL fair value
Fair Value of IXHL stock based on Discounted Cash Flow (DCF)
Price
$0.60
Fair Value
$0.22
Overvalued by
178.95%
IXHL ($0.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IXHL ($0.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IXHL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IXHL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
20.48x
Market
27.98x
IXHL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.1x
Industry
1.99x
IXHL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IXHL's financial health
Profit margin
Revenue
$12.0k
Net Income
-$5.9M
Profit Margin
-49,116.7%
IXHL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IXHL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.1M
Liabilities
$10.1M
Debt to equity
10.51
IXHL's short-term assets ($10.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IXHL's short-term assets ($10.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IXHL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
-$8.0k
Financing
$4.1M
IXHL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IXHL vs Pharmaceutical Stocks
Incannex Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.